{"organizations": [], "uuid": "56e0bf242efc73232fa1dde2c9e2ddca00c52173", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/gsk-teva-pharm-ind/teva-wins-reversal-of-u-s-jurys-235-mln-gsk-drug-patent-verdict-idUSL1N1RA1YH", "country": "US", "domain_rank": 408, "title": "Teva wins reversal of U.S. jury's $235 mln GSK drug patent verdict", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-28T22:18:00.000+03:00", "replies_count": 0, "uuid": "56e0bf242efc73232fa1dde2c9e2ddca00c52173"}, "author": "", "url": "https://www.reuters.com/article/gsk-teva-pharm-ind/teva-wins-reversal-of-u-s-jurys-235-mln-gsk-drug-patent-verdict-idUSL1N1RA1YH", "ord_in_thread": 0, "title": "Teva wins reversal of U.S. jury's $235 mln GSK drug patent verdict", "locations": [], "entities": {"persons": [{"name": "nate raymond", "sentiment": "none"}, {"name": "susan thomas", "sentiment": "none"}, {"name": "leonard stark", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "wilmington", "sentiment": "none"}, {"name": "delaware", "sentiment": "none"}, {"name": "boston", "sentiment": "none"}], "organizations": [{"name": "teva", "sentiment": "negative"}, {"name": "glaxosmithkline plc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "teva pharmaceutical industries ltd", "sentiment": "none"}, {"name": "gsk", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 28, 2018 / 7:20 PM / Updated 15 minutes ago Teva wins reversal of U.S. jury's $235 mln GSK drug patent verdict Reuters Staff 1 Min Read \nMarch 28 (Reuters) - A federal judge on Wednesday overturned a U.S. jury’s verdict that required Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg. \nU.S. District Judge Leonard Stark in Wilmington, Delaware ruled that the evidence did not support the jury’s finding in June that Teva sales of a generic version of the drug caused doctors to infringe GSK’s patent. (Reporting by Nate Raymond in Boston Editing by Susan Thomas)", "external_links": [], "published": "2018-03-28T22:18:00.000+03:00", "crawled": "2018-03-28T22:42:30.013+03:00", "highlightTitle": ""}